The pooled burden of HIV treatment failure and its associated factors in Ethiopian context is required to provide evidence towards renewed ambitious future goal.
BACKGROUND
The risk of death due to HIV has been decreased after the era of highly active antiretroviral therapy (HAART) (1) . Evidence has shown that individuals on HAART with an undetectable viral load, absence of advanced clinical finding, and high CD4 count are less likely to transmit HIV to others people (2, 3) . However, the risk of HIV transmission is high due to treatment failure. Treatment failure can be virological, immunological, or clinical failure. Virological failure is plasma viral load above 1000 copies/ ml based on two consecutive viral load measurements after 3 months, with adherence support. Immunological failure is CD4 count falls to the baseline (or below) or persistent CD4 levels below 100 cells/mm3 for adult and adolescent or below 200 cells/mm3 younger than 5 years. Clinical failure is defined as occurrence or recurrence of advanced WHO clinical stage or conditions after at least 6 months of therapy (4) .
Globally, UNAIDS' 90-90-90 planned to have 90% of people on HAART are virally suppressed by 2030 and as a result HIV treatment failure would be prevented (5) . Despite this ambitious goal, as of a systematic analysis of national HIV treatment cascades of 69 countries by 2016, viral suppression was between 68% in Switzerland and 7% in China (6) . It can be prevented through the implementation of globally recommended strategies. For instance, increase HAART adherence, taking medication based on the appropriate prescription, prevent drug-drug interaction, increasing knowledge and attitudes of patients towards HAART, timely initiation of HAART, prevention and control of opportunistic infections, and implementation of effective food and nutrition policy (7) (8) (9) (10) (11) .
A higher viral load may leads to HIV treatment failure, which is becoming a threat of different African countries, like in Burkina Faso (6.4%) (12) , Ghana (15.7%) (13) , and Tanzania (14.9%) (14) . In Ethiopia, virological, immunological, and clinical failure found to be in the range between 1.3% (15) to 11.5% (16), 2.1% (17) to 21% (18) , and 3.1% (19) to 12.3% (20) respectively.
With these variations of reports, there is no pooled representative national data in Ethiopia. In order to provide evidence towards renewed ambitious future goal, it is now critical to reflect the pooled burden of HIV treatment failure in Ethiopian context. The objective of this study was firstly, to estimate the national burden of HIV treatment failure and secondly, to review contextual factors of HIV treatment failure using globally accepted key performance indicators as a framework. Thus, this information will be helpful for healthcare professionals and further helps to enable the country to sustain its successes and identify and improve weaknesses towards the goal of ending AIDS.
METHODS

Reporting
It is reported based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline (21) (supplementary file-research checklist). Its protocol is registered in the Prospero database with a registration number CRD42018100254.
Search strategy
PubMed, Web of Science, Scopus, and Google Scholar databases were used to get the research articles. The search strategy made in PubMed was: [("Human Immunodeficiency virus"[MeSH Terms] OR HIV OR AIDS OR "Acquired Immunodeficiency syndrome" AND ("antiretroviral therapy"[MeSH Terms] OR "highly antiretroviral therapy" OR HAART OR ART OR "ARV Therapy" OR "antiretroviral therapy") AND (outcome OR "treatment failure" OR failure OR "virological failure" OR "immunological failure" OR "Clinical failure") AND (Ethiopia)]. The search done in PubMed through search terms was 03/10/2018. In addition, Ethiopian
Universities' (University of Gondar and Addis Ababa University) online repository library were searched. Endnote 7 reference manager software was used to manage duplicated references and for citation in the text.
Inclusion and exclusion criteria
Those articles included in this meta-analysis were: (1) cohort, case-control, and cross-sectional studies, (2) studies that reported the prevalence and/ or AOR (adjusted odd ratio) of associated factors of overall HAART treatment, immunological, clinical, and virological failure, (3) studies conducted in Ethiopia, and (4) studies published in English.
Studies without full-text access, qualitative studies, and conference proceeding without full-text report were excluded.
Outcome measurement
According to WHO (4) , HIV treatment failure could be clinical, immunological, and virological failure.
The prevalence of failure was ascertained by dividing the participants with the outcome of interests to the overall study participants multiplied by 100.
Quality assessment
Two authors assessed the quality of the articles based on Newcastle-Ottawa Scale quality assessment tool for cross-sectional, case control, and cohort studies (22) . The criteria for crosssectional studies has mainly three sections, in which the first section mainly focused on selection and graded by four stars, the second section dedicated with the comparability of the study and graded by two stars, and the third section emphasized on the outcome and graded by three stars.
The criteria for case control studies were: 1) selection evaluated by four stars, 2) comparability assessed by two stars, and 3) exposure graded by four stars. The criteria for cohort studies were: 1) selection graded by six stars, 2) comparability graded by two stars, and 3) outcome graded by five stars. Whenever disagreement happened between the two quality assessors, the procedure would be repeated and further solved by interference of third reviewer. Cross-sectional, casecontrol, and cohort studies scored 6 and/or above, 7 and/or above, and 9 and/or above quality assessment criteria were included respectively.
Data extraction process
Two authors extracted the required data. The first author and year of publication, sample size, an outcome of interest, study design, study population, geographical location of the study, fund, and response rate were collected. Laird random-effects model was employed to estimate the overall prevalence. Subgroup analysis based on geographical location of the study, treatment failure type, study population by age, and study design was conducted to see variation in outcomes. The sensitivity analysis was also employed to see whether the outlier result found in the included studies.
Data synthesis and statistical analysis
RESULTS
Search results
A total of 873 articles were found from search engines (Figure 1 ). 
Publication bias
Funnel plot for HIV treatment failure is shown below (Figure 2 ). Egger's regression test of pvalue for overall HIV treatment failure is 0.226. 
Meta-analysis
HIV treatment failure based on definition of HAART failure
A total of 4,738 participants in nine studies were used to estimate the pooled prevalence of HIV treatment failure based on the definition of HAART failure. The pooled prevalence of HIV treatment failure was 15.9% (95% CI: 11.6%-20.1%) (Figure 3 ). 
Immunological and Virological definition of HIV treatment failure
A total of 5,899 study participants in 13 studies were involved to determine HIV treatment failure based on immunological definition. Of which, 10.2% (6.9%-13.6%) developed immunological failure. Regarding virological failure, the pooled prevalence from six studies with a total of 2,406 participants was 5.6% (95% CI: 2.9%-8.3%).
Clinical definition of HIV treatment failure
he ws nt ed ith A total of 4,497 study participants in 9 studies found to estimate the clinical failure, in which the pooled prevalence was 6.3% (4.6%-8.0%).
Subgroup analysis
Subgroup analysis was employed based on region, age of the study participants, and study design. Lower prevalence of HIV treatment failure based on the definition of HAART, immunological, and virological failure is found in Amhara (13.7%), Tigray (6.5%), and Addis Ababa (1.5%) respectively.
Sensitivity Analysis
In the sensitivity analysis, the overall HIV treatment failure based on the definition of HAART 
Associated factors of HIV treatment failure
HIV treatment failure is attributed to clinical, drug and health system-related factors.
Clinical-related factors
The pooled effects of CD4 cell count <200 cells/mm3 (AOR=7.2; 95% CI: 2.5-12.0), ≤ 100 cells/ mm3 (AOR=2.1; 95% CI: 1.4-2.8) and <50 cells/mm3 (AOR=3.3; 95% CI: 1.4-5.3) as compared to those with >200, >100, and > 50 cells/mm3 on HIV treatment failure were estimated respectively.
The pooled effect of being on WHO clinical stage III/IV showed higher risk (AOR=1.9; 95% CI:
1.3-2.6) to HIV treatment failure as compared to stage II/I. The pooled effect presence of opportunistic infections (TB, diarrhea, pneumonia, other OIs) is more likely (AOR=1.8; 95% CI: 1.2-2.4) to exposed patients to HIV treatment failure.
Drug-related factors
The pooled effect of poor HAART adherence on HIV treatment failure was found to be 8.1 (95% CI: 4.3-11.8)
DISCUSSION
Our study has two main findings related to the national prevalence and risk factors for HIV treatment failure. First, we noted that using the definition of HAART failure, HIV treatment failure was 15.9% (95% CI: 11.6%-20.1%).
In Ethiopia threat of HIV treatment failure is becoming appointed discussion. This might be due to implementation of poor HIV care, delaying on recognition of symptom of treatment failure, (35) , late initiation of HAART (36) , high burden of opportunistic infections (37) , lack of well nutritional support (38) , ART associated adverse reaction, (39) and frequent psychological problem (40, 41) are recorded in Ethiopia. Besides, absence of frequent therapeutic drug monitors and/ or resistance testing while the patient is still on the suspect or failing regimen.
Though it is found that the WHO immunological criteria have a very low sensitivity and high specificity (42) , this finding showed that HIV treatment failure using immunological definition of treatment failure (10.2%) was higher than that of using clinical (6.3%) and virological (5.6%) definition of treatment failure. These variations might be due to the number of studies included to immunological definition of HIV treatment failure were many in number. The lower prevalence of HIV treatment failure using clinical definition might be due to limited diagnostic capabilities. Although only five studies were found to estimate virological failure that might result under-estimation, the third 90 target of UNAIDS seems to be achieved; there is a plan to achieve 90% of all people receiving ART will have viral suppression by 2020 (5) .
Based on the subgroup analysis, HIV treatment failure is lower in children. ART monitoring using clinical and immunological criteria is problematic in children, and misclassification rates using the WHO pediatric guidelines remain high (43) .
It is estimated that lower CD4 cell count and advance WHO clinical stage leads to HIV treatment failure. Another studies (44, 45) reported similar finding in other settings. The presence of opportunistic infections on the other had linked to CD4 cell level. As patients' immune status becomes compromised, the rate of viral replication increases. CD4 cell count is the back bone of immunity construction that helps the human body to protect from the disease and can be prevent HIV replication (46) . Poor HAART adherence found to have a great impact on the occurrence of HIV treatment failure. It is widely agreed that once treatment is initiated, it should not be interrupted. In Ethiopia, within 7 days, nearly 11.3% of children are poorly adhered to ART (47) . It is expected that as duration increased the probability of ART interruptions would be more likely. The same in adult HIV patients' treatment interruption is fall in the range between 11.8-25.8% (48, 49) .
HIV treatment failure in Ethiopia found to be high. The current finding will have health policy and clinical implication for therapeutic management decisions. Early identification of ART treatment failure allows patients a higher chance of success when switching to a second line ART. Report on HIV treatment failure will be used to monitor the progress of the national action plan of 90-90-90 strategies.
LIMITATION OF THE STUDY
Lack of studies in some geographical areas of Ethiopia and therefore the finding should be interpreted with caution.
